Q-omics provides the consensus-scored MIR4500 profile across patient tissues and cancer cell-line models. MIR4500 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, MIR4500 is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, MIR4500 RNA expression shows 6,589 significant gene co-expression associations, with the highest sampling consensus in UCEC. Together, these results highlight UCS, KIRC, and UCEC as cancer lineages where MIR4500 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4500 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4500 survival associations across molecular data types. MIR4500 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4500 RNA expression–survival associations across cancer types. High MIR4500 expression shows unfavorable associations in UCS, LUAD, CESC, ACC, BLCA and LAML. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for MIR4500 RNA expression.
This table summarizes MIR4500 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4500. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4500 shows lower tumor expression in THCA and higher tumor expression in KIRC. The KIRC box plot shows higher MIR4500 RNA expression in tumor versus normal tissue (log2 FC = +0.096, t-test p = .006).
This table shows molecular features associated with MIR4500 in patient tissues and cancer cell lines. In patient samples, MIR4500 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
